StockData
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. (LRMR) stock

LRMRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$2.99−0.01 (-0.33%)

Close on Nov 17, 2026Market cap $310.61MP/E –Yield –

Larimar Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Larimar Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$178.99M. For fiscal 2025 it was -$172.50M. The highest annual figure on record is -$13.78M in fiscal 2013.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$172.50M–
FY2024Dec 31, 2024-$90.89M–
FY2023Dec 31, 2023-$41.76M–
FY2022Dec 31, 2022-$36.53M–
FY2021Dec 31, 2021-$50.47M–
FY2020Dec 31, 2020-$42.80M–
FY2019Dec 31, 2019-$23.21M–
FY2018Dec 31, 2018-$61.12M–
FY2017Dec 31, 2017-$53.00M–
FY2016Dec 31, 2016-$58.23M–
FY2015Dec 31, 2015-$73.81M–
FY2014Dec 31, 2014-$35.53M–
FY2013Dec 31, 2013-$13.78M–
FY2012Dec 31, 2012-$13.79M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$34.35M–
Q1 FY2026Mar 31, 2026-$31.12M–
Q4 FY2025Dec 31, 2025-$64.02M–
Q3 FY2025Sep 30, 2025-$49.50M–
Q2 FY2025Jun 30, 2025-$27.79M–
Q1 FY2025Mar 31, 2025-$31.19M–
Q4 FY2024Dec 31, 2024-$31.29M–
Q3 FY2024Sep 30, 2024-$18.26M–
Q2 FY2024Jun 30, 2024-$24.60M–
Q1 FY2024Mar 31, 2024-$16.73M–
Q4 FY2023Dec 31, 2023-$14.16M–
Q3 FY2023Sep 30, 2023-$10.34M–
Q2 FY2023Jun 30, 2023-$9.62M–
Q1 FY2023Mar 31, 2023-$7.64M–
Q4 FY2022Dec 31, 2022-$10.44M–
Q3 FY2022Sep 30, 2022-$8.51M–
Q2 FY2022Jun 30, 2022-$8.69M–
Q1 FY2022Mar 31, 2022-$8.89M–
Q4 FY2021Dec 31, 2021-$9.09M–
Q3 FY2021Sep 30, 2021-$16.73M–
Q2 FY2021Jun 30, 2021-$12.54M–
Q1 FY2021Mar 31, 2021-$12.11M–
Q4 FY2020Dec 31, 2020-$14.40M–
Q3 FY2020Sep 30, 2020-$10.34M–
Q2 FY2020Jun 30, 2020-$11.40M–
Q1 FY2020Mar 31, 2020-$6.67M–
Q4 FY2019Dec 31, 2019-$6.16M–
Q3 FY2019Sep 30, 2019-$8.63M–
Q2 FY2019Jun 30, 2019-$3.70M–
Q1 FY2019Mar 31, 2019-$13.28M–
Q4 FY2018Dec 31, 2018-$14.69M–
Q3 FY2018Sep 30, 2018-$15.17M–
Q2 FY2018Jun 30, 2018-$15.56M–
Q1 FY2018Mar 31, 2018-$15.70M–
Q4 FY2017Dec 31, 2017-$13.36M–
Q3 FY2017Sep 30, 2017-$12.84M–
Q2 FY2017Jun 30, 2017-$13.54M–
Q1 FY2017Mar 31, 2017-$13.27M–
Q4 FY2016Dec 31, 2016-$10.48M–
Q3 FY2016Sep 30, 2016-$14.83M–

More Larimar Therapeutics figures

See a number that looks wrong?